The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Small Molecule NF-κB Pathway Inhibitors in Clinic
Open accessAbstract
Nuclear factor kappa B (NF-κB) signaling is implicated in all major human chronic diseases, with its role in transcription of hundreds of gene well established in the literature. This has propelled research into targeting the NF-κB pathways for modulating expression of those genes and the diseases mediated by them. In-spite of the critical, but often promiscuous role played by this pathway and the inhibition causing adverse drug reaction, currently many biologics, macromolecules, and small molecules that modulate this pathway are in the market or in clinical trials. Furthermore, many marketed drugs that were later found to also have NF-κB targeting activity were repurposed for new therapeutic interventions. Despite the rising importance of biologics in drug discovery, small molecules got around 76% of US-FDA (Food and Drug Administration-US) approval in the last decade. This encouraged us to review information regarding clinically relevant small molecule inhibitors of the NF-κB pathway from cell surface receptor stimulation to nuclear signaling. We have also highlighted the underexplored targets in this pathway that have potential to succeed in clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF‐κB
Chen, L., Mu, Y., & Greene, W. C. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf660 · Cited by 827
Inhibiting NF-κB activation by small molecules as a therapeutic strategy
Gupta, S. C., Sundaram, C., Reuter, S., & Aggarwal, B. B. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.004 · Cited by 762
Mechanisms of NF-κB p65 and strategies for therapeutic manipulation
Giridharan, S., & Srinivasan, M. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s140188 · Cited by 686
Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activation
Mahoney, D. J., Cheung, H. H., Mrad, R. L., Plenchette, S., Simard, C., Enwere, E., Arora, V., Mak, T. W., Lacasse, E. C., Waring, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711122105 · Cited by 540
Good cop, bad cop: the different faces of NF-κB
Perkins, N. D., & Gilmore, T. D. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401838 · Cited by 489
Inflammation and the Metabolic Syndrome: The Tissue-Specific Functions of NF-κB
Catrysse, L., & van Loo, G. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.01.006 · Cited by 329
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis
Waxman, A. J., Clasen, S., Hwang, W.-T., Garfall, A., Vogl, D. T., Carver, J., O’Quinn, R., Cohen, A. D., Stadtmauer, E. A., Ky, B., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4519 · Cited by 286
Nisr, R. B., Shah, D. S., Ganley, I. G., & Hundal, H. S. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03148-8 · Cited by 142
A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells
Kaltschmidt, C., Banz-Jansen, C., Benhidjeb, T., Beshay, M., Förster, C., Greiner, J., Hamelmann, E., Jorch, N., Mertzlufft, F., Pfitzenmaier, J., et al. (2019) · Cancers · doi:10.3390/cancers11050655 · Cited by 102
Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies
Hasan, M., & Yan, N. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.04.008 · Cited by 83
Tolcher, A. W., Bendell, J. C., Papadopoulos, K. P., Burris, H. A., Patnaik, A., Fairbrother, W. J., Wong, H., Budha, N., Darbonne, W. C., Peale, F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0308 · Cited by 33
Research works printed but not linked: 150
- Sen, 1986, Multiple nuclear factors interact with the immunoglobulin enhancer sequences, Cell, 46, 705, 10.1016/0092-8674(86)90346-6 · DOI · Paper page
- Ang, 2007, Notch and NFkappaB signaling pathways: Do they collaborate in normal vertebrate brain development and function?, Bioessays, 29, 1039, 10.1002/bies.20647 · DOI
- Correa, 2005, Zebrafish IkappaB kinase 1 negatively regulates NF-kappaB activity, Curr. Biol., 15, 1291, 10.1016/j.cub.2005.06.023 · DOI
- Garbati, 2011, Inhibition of NF-kB signaling as a strategy in disease therapy, NF-kB in Health and Disease. Current Topics in Microbiology and Immunology, Volume 349, 245
- Chew, 2018, Noncoding RNAs: Master regulators of inflammatory signaling, Trends Mol. Med., 24, 66, 10.1016/j.molmed.2017.11.003 · DOI · Paper page
- Li, 2016, Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas, Proc. Natl. Acad. Sci. USA, 113, 14402, 10.1073/pnas.1611106113 · DOI
- Ozturk, M.B., Li, Y., and Tergaonkar, V. (2017). Current insights to regulation and role of telomerase in human diseases. Antioxidants, 6. · DOI
- Puar, Y.R., Shanmugam, M.K., Fan, L., Arfuso, F., Sethi, G., and Tergaonkar, V. (2018). Evidence for the involvement of the master transcription factor NF-kappaB in cancer initiation and progression. Biomedicines, 6. · DOI · Paper page
- Xu, 2018, Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1, Nat. Commun., 9, 3183, 10.1038/s41467-018-05644-0 · DOI
- Cildir, 2017, The transcriptional program, functional heterogeneity, and clinical targeting of mast cells, J. Exp. Med., 214, 2491, 10.1084/jem.20170910 · DOI
- Khattar, 2019, Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy, Nat. Commun., 10, 5349, 10.1038/s41467-019-13082-9 · DOI
- Herscovitch, 2006, Inhibitors of NF-kB signaling: 785 and counting, Oncogene, 25, 6887, 10.1038/sj.onc.1209982 · DOI · Paper page
- Zhang, 2017, 30 Years of NF-kB: A blossoming of relevance to human pathobiology, Cell, 168, 37, 10.1016/j.cell.2016.12.012 · DOI · Paper page
- Hayden, 2012, NF-κB, the first quarter-century: Remarkable progress and outstanding questions, Genes Dev., 26, 203, 10.1101/gad.183434.111 · DOI · Paper page
- Sun, 2008, New insights into NF-κB regulation and function, Trends Immunol., 29, 469, 10.1016/j.it.2008.07.003 · DOI · Paper page
- Hayden, 2008, Shared principles in NF-κB signaling, Cell, 132, 344, 10.1016/j.cell.2008.01.020 · DOI · Paper page
- Vallabhapurapu, 2009, Regulation and function of NF-κB transcription factors in the immune system, Annu. Rev. Immunol., 27, 693, 10.1146/annurev.immunol.021908.132641 · DOI · Paper page
- Cildir, 2016, Noncanonical NF-kB Signaling in Health and Disease, Trends Mol. Med., 22, 414, 10.1016/j.molmed.2016.03.002 · DOI · Paper page
- Sun, 2012, The noncanonical NF-κB pathway, Immunol. Rev., 246, 125, 10.1111/j.1600-065X.2011.01088.x · DOI · Paper page
- Xiao, 2001, NF-κB-inducing kinase regulates the processing of NF-κB2 p100, Mol. Cell, 7, 401, 10.1016/S1097-2765(01)00187-3 · DOI · Paper page
- Herrington, 2016, Modulation of NF-κB signaling as a therapeutic target in autoimmunity, J. Biomol. Screen., 21, 223, 10.1177/1087057115617456 · DOI
- Fukuoka, M., Yoshioka, K., and Hohjoh, H. (2018). NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells. PLoS ONE, 13. · DOI
- Wang, 2020, Endocrinotherapy resistance of prostate and breast cancer: Importance of the NF-κB pathway, Int. J. Oncol., 56, 1064
- Bennett, 2018, NF-κB in the crosshairs: Rethinking an old riddle, Int. J. Biochem. Cell Biol., 95, 108, 10.1016/j.biocel.2017.12.020 · DOI
- Gurevich, 2014, Therapeutic potential of small molecules and engineered proteins, Handb. Exp. Pharmacol., 219, 1, 10.1007/978-3-642-41199-1_1 · DOI
- Nwibo, 2015, Small molecule drugs; down but not out: A future for medical research and therapeutics, IOSR JDMS, 14, 70
- Talevi, 2015, Multi-target pharmacology: Possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective, Front. Pharmacol., 6, 205, 10.3389/fphar.2015.00205 · DOI · Paper page
- Begalli, F., Bennett, J., Capece, D., Verzella, D., D’Andrea, D., Tornatore, L., and Franzoso, G. (2017). Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity. Biomedicines, 5. · DOI
- Tracey, 2008, Tumor necrosis factor antagonist mechanisms of action: A comprehensive review, Pharmacol. Ther., 117, 244, 10.1016/j.pharmthera.2007.10.001 · DOI · Paper page
- Ono, 2020, RANKL biology: Bone metabolism, the immune system, and beyond, Inflamm. Regen., 40, 2, 10.1186/s41232-019-0111-3 · DOI · Paper page
- Pileri, 2017, Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions, Blood Cancer J., 7, e603, 10.1038/bcj.2017.85 · DOI · Paper page
- Porter, 2019, Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer, Nat. Commun., 10, 1
- Anwar, 2019, Recent clinical trends in Toll-like receptor, Med. Res. Rev., 39, 1053, 10.1002/med.21553 · DOI · Paper page
- Novack, 2003, The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis, J. Exp. Med., 198, 771, 10.1084/jem.20030116 · DOI · Paper page
- Tyan, 2019, Rebound vertebral fractures in a patient with lung cancer after oncology-dose Denosumab discontinuation: A cautionary tale, MCP IQ O, 3, 235
- Jiang, 2019, Development of small-molecules targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)—Receptor Activator of Nuclear Factor-κB (RANK) protein–protein interaction by structure-based virtual screening and hit optimization, J. Med. Chem., 62, 5370, 10.1021/acs.jmedchem.8b02027 · DOI
- Kaptein, 2018, Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies, Blood, 132, 1871, 10.1182/blood-2018-99-109973 · doi:10.1182/blood-2018-99-109973
- Owen, 2019, Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma, Curr. Oncol., 26, e233, 10.3747/co.26.4345 · DOI
- Kutsch, 2019, A prospective, open-label, multicenter, phase 2 trial to evaluate the safety and efficacy of the combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), Blood, 134, 3047, 10.1182/blood-2019-131025 · doi:10.1182/blood-2019-131025
- Rule, 2020, Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059), Leukemia Vol., 34, 1458, 10.1038/s41375-019-0658-7 · DOI
- (2020, May 06). Sanofi Brain-Penetrant BTK Inhibitor Meets Primary Endpoint of Phase 2 Trial in Relapsing Multiple Sclerosis. Available online: https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-06-07-00-00.
- Chee, 2013, Phase II study of Dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas, Oncologist, 18, 1091, 10.1634/theoncologist.2013-0255 · DOI
- Tsou, 2014, Cellular Mechanisms of Tissue Fibrosis. 8. Current and future drug targets in fibrosis: Focus on Rho GTPase-regulated gene transcription, Am. J. Physiol. Cell Physiol., 307, C2, 10.1152/ajpcell.00060.2014 · DOI
- Levy, 2019, Five Ibrutinib-associated side effects that all clinicians should be aware of, Acta Haematol., 141, 254, 10.1159/000497356 · doi:10.1159/000497356
- Conchon, 2011, Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia, Rev. Bras. Hematol. Hemoter., 33, 131, 10.5581/1516-8484.20110034 · DOI
- Nagane, 2019, Phase 1/2 study of Tirabrutinib (ONO/GS-4059), a next-generation Bruton’s Tyrosine Kinase (BTK) inhibitor, monotherapy in patients with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL), Blood, 134, 1586, 10.1182/blood-2019-123362 · doi:10.1182/blood-2019-123362
- Song, 2019, Safety and efficacy of Orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle celllLymphoma: A multicenter, open-label, phase II study, Blood, 134, 755, 10.1182/blood-2019-126305 · doi:10.1182/blood-2019-126305
- Catlett, I.M., Nowak, M., Kundu, S., Zheng, N., Liu, A., He, B., Girgis, I.G., and Grasela, D.M. (2020). Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton’s tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants. Br. J. Clin. Pharmacol. · DOI
- Kumagai, 2019, FRI0156 a phase 1, single and multiple ascending dose study of TAS5315—A novel highly selective inhibitor of Bruton’s tyrosine kinase—in healthy male volunteers, Ann. Rheum. Dis., 78, 750
- Lee, 2017, Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants, Eur. J. Clin. Pharmacol., 73, 689, 10.1007/s00228-017-2226-2 · DOI
- Cohen, S.B. (2019, January 10). Efficacy and safety of Fenebrutinib, a BTK inhibitor, compared to placebo in rheumatoid arthritis patients with active disease despite TNF inhibitor treatment: Randomized, double blind, phase 2 study. Proceedings of the American College of Rheumatology, Atlanta, GA, USA.
- Jurczak, W.R., Townsend, W., Tucker, D., Sarholz, B., Scheele, J., Gribben, J., and Zinzani, P.L. (2018, January 19–23). PDPhase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies. Proceedings of the European Society for Medical Oncology (ESMO) congress, Munich, Germany. · DOI
- Danto, 2019, Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects, Arthritis Res. Ther., 21, 269, 10.1186/s13075-019-2008-6 · DOI
- Younes, 2019, Phase 1 dose-finding study investigating CA-4948, an IRAK4 kinase inhibitor, in patients with R/R NHL: Report of initial efficacy and updated safety information, Blood, 134, 5327, 10.1182/blood-2019-131851 · doi:10.1182/blood-2019-131851
- Rasco, 2019, A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors, J. Clin. Oncol., 37, 3125, 10.1200/JCO.2019.37.15_suppl.3125 · doi:10.1200/jco.2019.37.15_suppl.3125
- Pemmaraju, 2019, Final results of phase 2 clinical trial of LCL161, a novel oral SMAC mimetic/IAP antagonist, for patients with intermediate to high risk myelofibrosis, Blood, 134, 555, 10.1182/blood-2019-130046 · DOI
- Mita, 2020, A phase I study of ASTX660, an antagonist of inhibitors of apoptosis proteins, in adults with advanced cancers or lymphoma, Clin. Cancer Res., 26, 2819, 10.1158/1078-0432.CCR-19-1430 · DOI
- Rhyasen, 2015, IRAK signalling in cancer, Br. J. Cancer, 112, 232, 10.1038/bjc.2014.513 · DOI · Paper page
- Wang, 2009, IRAK-4 inhibitors for inflammation, Curr. Top. Med. Chem., 9, 724, 10.2174/156802609789044407 · DOI
- Singer, 2018, Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy, Oncotarget, 9, 33416, 10.18632/oncotarget.26058 · DOI
- (2020, May 05). Press Release on CU-4948 Phase 1 Study. Available online: http://investors.curis.com/2019-12-06-Curis-Provides-First-Ever-Demonstration-that-Targeting-IRAK4-in-Patients-with-Relapsed-Refractory-Non-Hodgkins-Lymphoma-Results-in-Anti-Cancer-Activity-in-Ongoing-Phase-1-Study.
- Ozes, 1999, NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase, Nature, 401, 82, 10.1038/43466 · DOI · Paper page
- Reddy, 1997, Phosphatidylinositol 3-kinase in interleukin 1 signaling. Physical interaction with the interleukin 1 receptor and requirement in NFkappaB and AP-1 activation, J. Biol. Chem., 272, 29167, 10.1074/jbc.272.46.29167 · DOI · Paper page
- Fruman, 2014, PI3K and cancer: Lessons, challenges and opportunities, Nat. Rev. Drug Discov., 13, 140, 10.1038/nrd4204 · DOI · Paper page
- Ghoneum, A., and Said, N. (2019). PI3K-AKT-mTOR and NFkappaB pathways in ovarian cancer: Implications for targeted therapeutics. Cancers, 11. · DOI · Paper page
- Pacold, 2000, Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma, Cell, 103, 931, 10.1016/S0092-8674(00)00196-3 · DOI · Paper page
- Guo, 2015, The PI3K/AKT pathway and renal cell carcinoma, J. Genet. Genomics, 42, 343, 10.1016/j.jgg.2015.03.003 · DOI · Paper page
- Yang, 2019, Targeting PI3K in cancer: Mechanisms and advances in clinical trials, Mol. Cancer, 18, 26, 10.1186/s12943-019-0954-x · DOI · Paper page
- Guo, 2019, Recent Advance of Akt Inhibitors in Clinical Trials, Chemistry Select, 4, 9040
- Mayer, 2016, The PI3K/AKT pathway as a target for cancer treatment, Annu. Rev. Med., 67, 11, 10.1146/annurev-med-062913-051343 · DOI · Paper page
- Michie, J., Kearney, C.J., Hawkins, E.D., Silke, J., and Oliaro, J. (2020). The immuno-modulatory effects of inhibitor of apoptosis protein antagonists in cancer immunotherapy. Cells, 9. · DOI
- Zhang, 2019, Ubiquitin ligases cIAP1 and cIAP2 limit cell death to prevent inflammation, Cell Rep., 27, 2679.e2673, 10.1016/j.celrep.2019.04.111 · DOI
- Ea, 2006, Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO, Mol. Cell, 22, 245, 10.1016/j.molcel.2006.03.026 · DOI · Paper page
- Guicciardi, M.E., Werneburg, N.W., Bronk, S.F., Franke, A., Yagita, H., Thomas, G., and Gores, G.J. (2014). Cellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurin acidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity. PLoS ONE, 9. · DOI
- Sun, 2014, Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells, ACS Chem. Biol., 9, 994, 10.1021/cb400889a · DOI
- (2020, May 06). EMA grants Orphan Drug Designation to Debiopharm International SA’sIAP inhibitor Debio 1143 in the Treatment of Ovarian Cancer. Available online: https://www.debiopharm.com/drug-development/press-releases/ema-grants-orphan-drug-designation-to-debiopharm-international-sas-iap-inhibitor-debio-1143-in-the-treatment-of-ovarian-cancer/.
- Prescott, J.A., and Cook, S.J. (2018). Targeting IKKβ in cancer: Challenges and opportunities for the therapeutic utilisation of IKKβ inhibitors. Cell, 7. · DOI
- Xu, 2009, A ubiquitin replacement strategy in human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-1beta, Mol. Cell, 36, 302, 10.1016/j.molcel.2009.10.002 · DOI · Paper page
- Wang, 2001, TAK1 is a ubiquitin-dependent kinase of MKK and IKK, Nature, 412, 346, 10.1038/35085597 · DOI · Paper page
- Weber, 2000, Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β, Gastroenterology, 119, 1209, 10.1053/gast.2000.19458 · DOI · Paper page
- Yin, 1998, The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta, Nature, 396, 77, 10.1038/23948 · DOI · Paper page
- Goldfine, 2008, Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes, Clin. Transl. Sci., 1, 36, 10.1111/j.1752-8062.2008.00026.x · DOI · Paper page
- Sepulveda, 2007, Amelioration of chronic murine colitis by peptide-mediated transduction of the IkB kinase inhibitor NEMO binding domain peptide, J. Immunol., 179, 7852, 10.4049/jimmunol.179.11.7852 · DOI
- Rhodes, 2018, Cell-permeable bicyclic peptidyl inhibitors against NEMO-IκB kinase interaction directly from a combinatorial library, J. Am. Chem. Soc., 140, 12102, 10.1021/jacs.8b06738 · DOI
- Verhelst, 2013, IκB kinase ε (IKKε): A therapeutic target in inflammation and cancer, Biochem. Pharmacol., 85, 873, 10.1016/j.bcp.2013.01.007 · DOI
- Hovstadius, 2002, A Phase I study of CHS 828 in patients with solid tumor malignancy, Clin. Cancer Res., 8, 2843
- Grothe, 2017, IkappaB kinase inhibition as a potential treatment of osteoarthritis—Results of a clinical proof-of-concept study, Osteoarthr. Cartilage, 25, 46, 10.1016/j.joca.2016.08.010 · DOI
- Stansfield, 2017, New Substituted Cyanoindoline Derivatives as MAP3K14 Kinase Inhibitors for the Treatment of Cancer and Autoimmune Disorders, ACS Med. Chem. Lett., 8, 908, 10.1021/acsmedchemlett.7b00330 · doi:10.1021/acsmedchemlett.7b00330
- Pohl, 2019, Cellular quality control by the ubiquitin-proteasome system and autophagy, Science, 366, 818, 10.1126/science.aax3769 · DOI · Paper page
- Thibaudeau, 2019, A Practical Review of Proteasome Pharmacology, Pharmacol. Rev., 71, 170, 10.1124/pr.117.015370 · DOI · Paper page
- Clague, 2015, The demographics of the ubiquitin system, Trends Cell Biol., 25, 417, 10.1016/j.tcb.2015.03.002 · DOI · Paper page
- Myung, 2001, The ubiquitin-proteasome pathway and proteasome inhibitors, Med. Res. Rev., 21, 245, 10.1002/med.1009 · DOI · Paper page
- Ohtake, 2017, The emerging complexity of ubiquitin architecture, J. Biochem., 161, 125
- Meyer, 2014, Enhanced protein degradation by branched ubiquitin chains, Cell, 157, 910, 10.1016/j.cell.2014.03.037 · DOI · Paper page
- Ohtake, 2016, The K48-K63 branched ubiquitin chain regulates NF-kappaB signaling, Mol. Cell, 64, 251, 10.1016/j.molcel.2016.09.014 · DOI · Paper page
- Sherman, D.J., and Li, J. (2020). Proteasome inhibitors: Harnessing proteostasis to combat disease. Molecules, 25. · DOI
- Huang, 2014, Efficacy of therapy with bortezomib in solid tumors: A review based on 32 clinical trials, Future Oncol. Lond. Engl., 10, 1795, 10.2217/fon.14.30 · DOI
- Gupta, 2019, Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor, Clin. Pharmacokinet., 58, 431, 10.1007/s40262-018-0702-1 · DOI
- Perel, 2016, Carfilzomib (Kyprolis): A novel proteasome inhibitor for relapsed and/or refractory multiple myeloma, P T, 41, 303
- Camargo, M., Farouk, S., and Campbell, K. (2017, January 1–3). Help or hindrance? An atypical presentation of Carfilzomib-induced nephrotoxicity. Proceedings of the 19th International Conference on Dialysis, Advances in CKD, Las Vegas, NV, USA.
- Roth, 2019, EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma, J. Clin. Oncol., 37, TPS2072, 10.1200/JCO.2019.37.15_suppl.TPS2072 · doi:10.1200/jco.2019.37.15_suppl.tps2072
- Cvek, 2008, The value of proteasome inhibition in cancer: Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?, Drug Discov. Today, 13, 716, 10.1016/j.drudis.2008.05.003 · DOI
- Ekinci, 2019, Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents, Recent Pat. Anti-Canc., 14, 113
- Morgan, 2006, Bortezomib (Velcadetrade mark) in the treatment of multiple myeloma, Ther. Clin. Risk Manag., 2, 271, 10.2147/tcrm.2006.2.3.271 · DOI · Paper page
- Siegel, 2013, From clinical trials to clinical practice: Single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma, Ther. Adv. Hematol., 4, 354, 10.1177/2040620713511176 · DOI
- McBride, 2013, The side effect profile of Carfilzomib: From clinical trials to clinical practice, J. Adv. Pract. Oncol., 4, 22
- Potts, 2011, Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework for clinical trials, Curr. Cancer Drug Targets, 11, 254, 10.2174/156800911794519716 · DOI · Paper page
- Rajan, 2016, New investigational drugs with single-agent activity in multiple myeloma, Blood Cancer J., 6, e451, 10.1038/bcj.2016.53 · DOI
- Swords, 2017, Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes, Blood Cancer J., 7, e520, 10.1038/bcj.2017.1 · DOI
- Soucy, 2010, The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy, Genes Cancer, 1, 708, 10.1177/1947601910382898 · DOI · Paper page
- Zhou, 2019, Neddylation: A novel modulator of the tumor microenvironment, Mol. Cancer, 18, 77, 10.1186/s12943-019-0979-1 · DOI · Paper page
- LianLiang, 2013, KPNB1, XPO7 and IPO8 mediate the translocation of NF-κB/p65 into the nucleus, Traffic, 14, 1132, 10.1111/tra.12097 · DOI
- Fagerlund, 2005, NF-{kappa} B is transported into the nucleus by importin {alpha}3 and importin {alpha}4, J. Biol. Chem., 280, 15942, 10.1074/jbc.M500814200 · DOI · Paper page
- Viatour, 2005, Phosphorylation of NF-kappaB and IkappaB proteins: Implications in cancer and inflammation, Trends Biochem. Sci., 30, 43, 10.1016/j.tibs.2004.11.009 · DOI · Paper page
- Huang, 2010, Posttranslational modifications of NF-kappaB: Another layer of regulation for NF-kappaB signaling pathway, Cell Signal, 22, 1282, 10.1016/j.cellsig.2010.03.017 · DOI · Paper page
- Kim, 2012, New molecular bridge between RelA/p65 and NF-κB target genes via histone acetyltransferase TIP60 cofactor, J. Biol. Chem., 7780-91, 287
- Kiernan, 2003, Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65, J. Biol. Chem., 278, 2758, 10.1074/jbc.M209572200 · DOI · Paper page
- Hajmirza, A., Emadali, A., Gauthier, A., Casasnovas, O., Gressin, R., and Callanan, M.B. (2018). BET family protein BRD4: An emerging actor in NFκB signaling in inflammation and cancer. Biomedicines, 6. · DOI
- Mathew, C., and Ghildyal, R. (2017). CRM1 inhibitors for antiviral therapy. Front. Microbiol., 8. · doi:10.3389/fmicb.2017.01171
- Bachelerie, 1997, Evidence for a role of CRM1 in signal-mediated nuclear protein export, Science, 278, 141, 10.1126/science.278.5335.141 · DOI · Paper page
- Wolff, 1997, Leptomycin B is an inhibitor of nuclear export: Inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-l) Rev protein and Rev-dependent mRNA, Chem. Biol., 4, 139, 10.1016/S1074-5521(97)90257-X · DOI · Paper page
- Kosyna, F.K., and Depping, R. (2018). Controlling the gatekeeper: Therapeutic targeting of nuclear transport. Cells, 7. · DOI
- Sadowski, 2018, Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma, BMC Vet. Res., 14, 1, 10.1186/s12917-018-1587-9 · doi:10.1186/s12917-018-1587-9
- Wang, 2019, The past, present, and future of CRM1/XPO1 inhibitors, Stem Cell Investig., 6, 6, 10.21037/sci.2019.02.03 · DOI
- Gavriatopoulou, M., Chari, A., Chen, C., Bahlis, N., Vogl, D.T., Jakubowiak, A., Dingli, D., Cornell, R.F., Hofmeister, C.C., and Siegel, D. (2020). Integrated safety profile of selinexor in multiple myeloma: Experience from 437 patients enrolled in clinical trials. Leukemia. · DOI
- Bubna, 2015, Vorinostat-An Overview, Indian J. Dermatol., 60, 419, 10.4103/0019-5154.160511 · DOI
- Liu, 2016, Efficacy and safety of Panobinostat in relapsed or/and refractory multiple myeloma: Meta analyses of clinical trials and systematic review, Sci. Rep., 6, 27361, 10.1038/srep27361 · DOI
- Zhang, 2018, Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer, Chin. J. Cancer Res., 30, 605, 10.21147/j.issn.1000-9604.2018.06.05 · DOI
- Khan, 2012, Azacitidine in the management of patients with myelodysplastic syndromes, Ther. Adv. Hematol., 3, 355, 10.1177/2040620712464882 · DOI
- Saba, 2007, Decitabine in the treatment of myelodysplastic syndromes, Ther. Clin. Risk Manag., 3, 807
- Wagstaff, 2012, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem. J., 443, 851, 10.1042/BJ20120150 · DOI · Paper page
- Soderholm, 2011, Importazole, a small molecule inhibitor of the Transport Receptor Importin-β, ACS Chem. Biol., 6, 700, 10.1021/cb2000296 · DOI · Paper page
- Lin, 1995, Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence, J. Biol. Chem., 270, 14255, 10.1074/jbc.270.24.14255 · DOI · Paper page
- Wang, 2011, A Cell-penetrating peptide suppresses inflammation by inhibiting NF-κB signaling, Mol. Ther., 19, 1849, 10.1038/mt.2011.82 · DOI
- Perkins, 2008, Regulation of the RelA (p65) transactivation domain, Biochem. Soc. Trans., 36, 603, 10.1042/BST0360603 · DOI
- Lecoq, 2017, Structural characterization of interactions between transactivation domain 1 of the p65 subunit of NF-kappaB and transcription regulatory factors, Nucleic Acids Res., 45, 5564, 10.1093/nar/gkx146 · DOI
- Rothgiesser, K.M., Fey, M., and Hottiger, M.O. (2010). Acetylation of p65 at lysine 314 is important for late NF-kappaB-dependent gene expression. BMC Genom., 11. · DOI
- Drahos, 2020, Current trends in the analysis of post-translational modifications, Chromatographia, 83, 1, 10.1007/s10337-019-03796-9 · DOI
- Yuksel, 2003, Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes, J. Pharmacol. Exp. Ther., 305, 298, 10.1124/jpet.102.041988 · DOI
- Hoffman, 2019, Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function, Neurology, 93, e1312, 10.1212/WNL.0000000000008168 · DOI
- Zimmermann, 2018, The immunomodulatory effects of macrolides—A systematic review of the underlying mechanisms, Front. Immunol., 9, 302, 10.3389/fimmu.2018.00302 · DOI · Paper page
- Sugawara, 2016, Non-antibiotic 12-membered macrolides: Design, synthesis and biological evaluation in a cigarette-smoking model, J. Antibiot. (Tokyo), 69, 319, 10.1038/ja.2015.91 · doi:10.1038/ja.2015.91
- Niloo, 2015, Plant polyphenols as inhibitors of NF-κB induced cytokine production—a potential anti-inflammatory treatment for Alzheimer’s disease?, Front. Mol. Neurosci., 8, 24
- Shimizu, 2019, Anti-inflammatory action of Curcumin and its use in the treatment of lifestyle-related diseases, Eur. Cardiol., 14, 117, 10.15420/ecr.2019.17.2 · DOI
- Sharifi-Rad, M., Pezzani, R., Redaelli, M., Zorzan, M., Imran, M., Ahmed Khalil, A., Salehi, B., Sharopov, F., Cho, W.C., and Sharifi-Rad, J. (2020). Preclinical activities of Epigallocatechin gallate in signaling pathways in cancer. Molecules, 25. · DOI
- Xie, 2020, Iguratimod as a new drug for rheumatoid arthritis: Current landscape, Front. Pharmacol., 11, 73, 10.3389/fphar.2020.00073 · doi:10.3389/fphar.2020.00073
- Li, 2018, Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway, Sci. Rep., 8, 1933, 10.1038/s41598-018-20390-5 · DOI
- Ehsanian, 2011, Beyond DNA binding—A review of the potential mechanisms mediating quinacrine’s therapeutic activities in parasitic infections, inflammation, and cancers, Cell Commun. Signal, 9, 13, 10.1186/1478-811X-9-13 · DOI
- Martin, 2001, Dimethylfumarate inhibits Tumor-Necrosis-Factor-induced CD62E expression in an NF-κB-dependent manner, J. Invest. Dermatol., 117, 1363, 10.1046/j.0022-202x.2001.01576.x · DOI
- Yan, B., Kuick, C.H., Lim, M., Venkataraman, K., Tennakoon, C., Loh, E., Lian, D., Leong, M.Y., Lakshmanan, M., and Tergaonkar, V. (2014). Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas. PLoS ONE, 9. · DOI
Cited by
Pathogenesis of allergic diseases and implications for therapeutic interventions
Wang, J., Zhou, Y., Zhang, H., Hu, L., Liu, J., Wang, L., Wang, T., Zhang, H., Cong, L., & Wang, Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01344-4 · Cited by 376
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Estupiñán, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 267
Mirzaei, S., Saghari, S., Bassiri, F., Raesi, R., Zarrabi, A., Hushmandi, K., Sethi, G., & Tergaonkar, V. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30759 · Cited by 243
Self-citationLin, Y.-N., Mesquita, T., Sanchez, L., Chen, Y.-H., Liu, W., Li, C., Rogers, R., Wang, Y., Li, X., Wu, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab419 · Cited by 83
Noncanonical NF-κB Signaling Pathway in Liver Diseases
Chen, Q., Lu, X., & Zhang, X. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00063 · Cited by 30
Metadata
- Authors
- Ramadass, V., Vaiyapuri, T., & Tergaonkar, V.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-07-21
- Volume
- 21
- Issue
- 14
- Pages
- 5164
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3044714181
- Cited by
- 210
- References
- 13
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Research Foundation Singapore (NRF-CRP17-2017-02)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.